Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT6026 Monotherapy and in Combination with BAT1308 in Advanced Solid Tumours
NCT05109650Phase 1Terminated
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Feb 2022
- Primary completion
- Mar 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAT6026 in solid tumor (advanced stage) (6 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose-limiting toxicity and Serious adverse event. Started Feb 2022; status: terminated.
02
Drugs
BAT6026
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05109650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05109650.